The prokineticins: Neuromodulators and mediators of inflammation and myeloid cell-dependent angiogenesis

Physiological Reviews

Volumn 98, Issue 2, 2018, Pages 1055-1082

  Negri, Lucia ^a   Ferrara, Napoleone ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GROWTH FACTOR; PROKINETICIN; UNCLASSIFIED DRUG; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AUTACOID;

ANGIOGENESIS; ARTICLE; AUTOIMMUNITY; BONE MARROW CELL; CARCINOGENESIS; CHRONIC PAIN; CIRCADIAN RHYTHM; HOMEOSTASIS; HUMAN; INFLAMMATION; INFLAMMATORY PAIN; INTESTINE INNERVATION; KALLMANN SYNDROME; MOOD; NERVOUS SYSTEM DEVELOPMENT; NEUROMODULATION; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PATHOPHYSIOLOGY; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; ANIMAL; CELL MOTION; METABOLISM; PHYSIOLOGY;

ANIMALS; CELL MOVEMENT; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; MYELOID CELLS; NEUROTRANSMITTER AGENTS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 85044828809     PISSN: 00319333     EISSN: 15221210     Source Type: Journal    
DOI: 10.1152/physrev.00012.2017     Document Type: Article

References (254)

1. Abou-Hamdan M, Costanza M, Fontana E, Di Dario M, Musio S, Congiu C, Onnis V, Lattanzi R, Radaelli M, Martinelli V, Salvadori S, Negri L, Poliani PL, Farina C, Balboni G, Steinman L, Pedotti R. Critical role for prokineticin 2 in CNS autoimmunity. Neurol Neuroimmunol Neuroinflamm 2: e95, 2015. doi: 10.1212/NXI.0000000000000095.
2. Abreu AP, Noel SD, Xu S, Carroll RS, Latronico AC, Kaiser UB. Evidence of the importance of the first intracellular loop of prokineticin receptor 2 in receptor function. Mol Endocrinol 26: 1417-1427, 2012. doi: 10.1210/me.2012-1102.
3. Alfaidy N. Prokineticin1 and pregnancy. Ann Endocrinol (Paris) 77: 101-104, 2016. doi: 10.1016/j.ando.2016.04.014.
4. Alfaidy N, Hoffmann P, Boufettal H, Samouh N, Aboussaouira T, Benharouga M, Feige JJ, Brouillet S. The multiple roles of EG-VEGF/PROK1 in normal and pathological placental angiogenesis. BioMed Res Int 2014: 451906, 2014. doi: 10.1155/2014/451906.
5. Aliper AM, Frieden-Korovkina VP, Buzdin A, Roumiantsev SA, Zhavoronkov A. A role for G-CSF and GM-CSF in nonmyeloid cancers. Cancer Med 3: 737-746, 2014. doi: 10.1002/cam4.239.
6. Asakura Y, Muroya K, Hanakawa J, Sato T, Aida N, Narumi S, Hasegawa T, Adachi M. Combined pituitary hormone deficiency with unique pituitary dysplasia and morning glory syndrome related to a heterozygous PROKR2 mutation. Clin Pediatr Endocrinol 24: 27-32, 2015. doi: 10.1297/cpe.24.27.
7. Balasubramanian R, Cohen DA, Klerman EB, Pignatelli D, Hall JE, Dwyer AA, Czeisler CA, Pitteloud N, Crowley WF. Absence of central circadian pacemaker abnormalities in humans with loss of function mutation in prokineticin 2. J Clin Endocrinol Metab 99: E561-E566, 2014. doi: 10.1210/jc.2013-2096.
8. Balasubramanian R, Plummer L, Sidis Y, Pitteloud N, Martin C, Zhou QY, Crowley WF Jr. The puzzles of the prokineticin 2 pathway in human reproduction. Mol Cell Endocrinol 346: 44-50, 2011. doi: 10.1016/j.mce.2011.05.040.
9. Balboni G, Lazzari I, Trapella C, Negri L, Lattanzi R, Giannini E, Nicotra A, Melchiorri P, Visentin S, Nuccio CD, Salvadori S. Triazine compounds as antagonists at Bv8- prokineticin receptors. J Med Chem 51: 7635-7639, 2008. doi: 10.1021/jm800854e.
10. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001. doi: 10.1016/S0140-6736(00)04046-0.
11. Bălu S, Pirtea L, Gaje P, Cîmpean AM, Raica M. The immunohistochemical expression of endocrine gland-derived-VEGF (EG-VEGF) as a prognostic marker in ovarian cancer. Rom J Morphol Embryol 53: 479-483, 2012.
12. Battersby S, Critchley HO, Morgan K, Millar RP, Jabbour HN. Expression and regulation of the prokineticins (endocrine gland-derived vascular endothelial growth factor and Bv8) and their receptors in the human endometrium across the menstrual cycle. J Clin Endocrinol Metab 89: 2463-2469, 2004. doi: 10.1210/jc.2003-032012.
13. Beale K, Gardiner JV, Bewick GA, Hostomska K, Patel NA, Hussain SS, Jayasena CN, Ebling FJ, Jethwa PH, Prosser HM, Lattanzi R, Negri L, Ghatei MA, Bloom SR, Dhillo WS. Peripheral administration of prokineticin 2 potently reduces food intake and body weight in mice via the brainstem. Br J Pharmacol 168: 403-410, 2013. doi: 10.1111/j.1476-5381.2012.02191.x.
14. Bendall LJ, Bradstock KF. G-CSF: from granulopoietic stimulant to bone marrow stem cell mobilizing agent. Cytokine Growth Factor Rev 25: 355-367, 2014. doi: 10.1016/j.cytogfr.2014.07.011.
15. Bendelac A, Fearon DT. Innate pathways that control acquired immunity. Curr Opin Immunol 9: 1-3, 1997. doi: 10.1016/S0952-7915(97)80151-3.
16. Boehm U, Bouloux PM, Dattani MT, de Roux N, Dodé C, Dunkel L, Dwyer AA, Giacobini P, Hardelin JP, Juul A, Maghnie M, Pitteloud N, Prevot V, Raivio T, Tena-Sempere M, Quinton R, Young J. European Consensus Statement on congenital hypogonadotropic hypogonadism-pathogenesis, diagnosis and treatment. Nat Rev Endocrinol 11: 547-564, 2015. doi: 10.1038/nrendo.2015.112.
17. Boisbouvier J, Albrand JP, Blackledge M, Jaquinod M, Schweitz H, Lazdunski M, Marion D. A structural homologue of colipase in black mamba venom revealed by NMR floating disulphide bridge analysis. J Mol Biol 283: 205-219, 1998. doi: 10.1006/jmbi.1998.2057.
18. Boyce S, Wyatt A, Webb JK, O’Donnell R, Mason G, Rigby M, Sirinathsinghji D, Hill RG, Rupniak NM. Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology 38: 611-623, 1999. doi: 10.1016/S0028-3908(98)00218-4.
19. Braun SM, Jessberger S. Adult neurogenesis: mechanisms and functional significance. Development 141: 1983-1986, 2014. doi: 10.1242/dev.104596.
20. Brouillet S, Hoffmann P, Benharouga M, Salomon A, Schaal JP, Feige JJ, Alfaidy N. Molecular characterization of EG-VEGF-mediated angiogenesis: differential effects on microvascular and macrovascular endothelial cells. Mol Biol Cell 21: 2832-2843, 2010. doi: 10.1091/mbc.E10-01-0059.
21. Brouillet S, Hoffmann P, Feige JJ, Alfaidy N. EG-VEGF: a key endocrine factor in placental development. Trends Endocrinol Metab 23: 501-508, 2012. doi: 10.1016/j.tem.2012.05.006.
22. Brouillet S, Murthi P, Hoffmann P, Salomon A, Sergent F, De Mazancourt P, Dakouane-Giudicelli M, Dieudonné MN, Rozenberg P, Vaiman D, Barbaux S, Benharouga M, Feige JJ, Alfaidy N. EG-VEGF controls placental growth and survival in normal and pathological pregnancies: case of fetal growth restriction (FGR). Cell Mol Life Sci 70: 511-525, 2013. doi: 10.1007/s00018-012-1141-z.
23. Bullock CM, Li JD, Zhou QY. Structural determinants required for the bioactivities of prokineticins and identification of prokineticin receptor antagonists. Mol Pharmacol 65: 582-588, 2004. doi: 10.1124/mol.65.3.582.
24. Burton KJ, Li X, Li B, Cheng MY, Urbanski HF, Zhou QY. Expression of prokineticin 2 and its receptor in the macaque monkey brain. Chronobiol Int 33: 191-199, 2016. doi: 10.3109/07420528.2015.1125361.
25. Burton KJ, Li X, Li JD, Hu WP, Zhou QY. Rhythmic Trafficking of TRPV2 in the Suprachiasmatic Nucleus Is Regulated by Prokineticin 2 Signaling. J Circadian Rhythms 13: 2, 2015. doi: 10.5334/jcr.ad.
26. Caioli S, Severini C, Ciotti T, Florenzano F, Pimpinella D, Petrocchi Passeri P, Balboni G, Polisca P, Lattanzi R, Nisticò R, Negri L, Zona C. Prokineticin system modulation as a new target to counteract the amyloid beta toxicity induced by glutamatergic alterations in an in vitro model of Alzheimer’s disease. Neuropharmacology 116: 82-97, 2017. doi: 10.1016/j.neuropharm.2016.12.012.
27. Campochiaro PA, Hafiz G, Mir TA, Scott AW, Zimmer-Galler I, Shah SM, Wenick AS, Brady CJ, Han I, He L, Channa R, Poon D, Meyerle C, Aronow MB, Sodhi A, Handa JT, Kherani S, Han Y, Sophie R, Wang G, Qian J. Pro-permeability Factors in Diabetic Macular Edema; the Diabetic Macular Edema Treated With Ozurdex Trial. Am J Ophthalmol 168: 13-23, 2016. doi: 10.1016/j.ajo.2016.04.017.
28. Casbon AJ, Reynaud D, Park C, Khuc E, Gan DD, Schepers K, Passegué E, Werb Z. Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc Natl Acad Sci USA 112: E566-E575, 2015. doi: 10.1073/pnas.1424927112.
29. Castelli M, Amodeo G, Negri L, Lattanzi R, Maftei D, Gotti C, Pistillo F, Onnis V, Congu C, Panerai AE, Sacerdote P, Franchi S. Antagonism of the Prokineticin System Prevents and Reverses Allodynia and Inflammation in a Mouse Model of Diabetes. PLoS One 11: e0146259, 2016. doi: 10.1371/journal.pone.0146259.
30. Chakraborty S, Keenportz B, Woodward S, Anderson J, Colan D. Paraneoplastic leukemoid reaction in solid tumors. Am J Clin Oncol 38: 326-330, 2015. doi: 10.1097/COC.0b013e3182a530dd.
31. Chaly AL, Srisai D, Gardner EE, Sebag JA. The Melanocortin Receptor Accessory Protein 2 promotes food intake through inhibition of the Prokineticin Receptor-1. eLife 5: e12397, 2016. doi: 10.7554/eLife.12397.
32. Chen J, Kuei C, Sutton S, Wilson S, Yu J, Kamme F, Mazur C, Lovenberg T, Liu C. Identification and pharmacological characterization of prokineticin 2 beta as a selective ligand for prokineticin receptor 1. Mol Pharmacol 67: 2070-2076, 2005. doi: 10.1124/mol.105.011619.
33. Chen T, Xue Y, Zhou M, Shaw C. Molecular cloning of mRNA from toad granular gland secretion and lyophilized skin: identification of Bo8-a novel prokineticin from Bombina orientalis. Peptides 26: 377-383, 2005. doi: 10.1016/j.peptides.2004.10.021.
34. Cheng MY, Bittman EL, Hattar S, Zhou QY. Regulation of prokineticin 2 expression by light and the circadian clock. BMC Neurosci 6: 17, 2005. doi: 10.1186/1471-2202-6-17.
35. Cheng MY, Bullock CM, Li C, Lee AG, Bermak JC, Belluzzi J, Weaver DR, Leslie FM, Zhou QY. Prokineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus. Nature 417: 405-410, 2002. doi: 10.1038/417405a.
36. Cheng MY, Lee AG, Culbertson C, Sun G, Talati RK, Manley NC, Li X, Zhao H, Lyons DM, Zhou QY, Steinberg GK, Sapolsky RM. Prokineticin 2 is an endangering mediator of cerebral ischemic injury. Proc Natl Acad Sci USA 109: 5475-5480, 2012. doi: 10.1073/pnas.1113363109.
37. Cheng MY, Leslie FM, Zhou QY. Expression of prokineticins and their receptors in the adult mouse brain. J Comp Neurol 498: 796-809, 2006. doi: 10.1002/cne.21087.
38. Choke E, Cockerill GW, Laing K, Dawson J, Wilson WR, Loftus IM, Thompson MM. Whole genome-expression profiling reveals a role for immune and inflammatory response in abdominal aortic aneurysm rupture. Eur J Vasc Endovasc Surg 37: 305-310, 2009. doi: 10.1016/j.ejvs.2008.11.017.
39. Chung AS, Ferrara N. Developmental and pathological angiogenesis. Annu Rev Cell Dev Biol 27: 563-584, 2011. doi: 10.1146/annurev-cellbio-092910-154002.
40. Chung AS, Lee J, Ferrara N. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer 10: 505-514, 2010. doi: 10.1038/nrc2868.
41. Chung AS, Wu X, Zhuang G, Ngu H, Kasman I, Zhang J, Vernes JM, Jiang Z, Meng YG, Peale FV, Ouyang W, Ferrara N. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med 19: 1114-1123, 2013. doi: 10.1038/nm.3291.
42. Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, Chen J, Chow B, Chui C, Crowley C, Currell B, Deuel B, Dowd P, Eaton D, Foster J, Grimaldi C, Gu Q, Hass PE, Heldens S, Huang A, Kim HS, Klimowski L, Jin Y, Johnson S, Lee J, Lewis L, Liao D, Mark M, Robbie E, Sanchez C, Schoenfeld J, Seshagiri S, Simmons L, Singh J, Smith V, Stinson J, Vagts A, Vandlen R, Watanabe C, Wieand D, Woods K, Xie MH, Yansura D, Yi S, Yu G, Yuan J, Zhang M, Zhang Z, Goddard A, Wood WI, Godowski P, Gray A. The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res 13: 2265-2270, 2003. doi: 10.1101/gr.1293003.
43. Clement PB. Histology of the ovary. Am J Surg Pathol 11: 277-303, 1987. doi: 10.1097/00000478-198704000-00006.
44. Coffelt SB, Kersten K, Doornebal CW, Weiden J, Vrijland K, Hau CS, Verstegen NJM, Ciampricotti M, Hawinkels LJAC, Jonkers J, de Visser KE. IL-17-producing __ T cells and neutrophils conspire to promote breast cancer metastasis. Nature 522: 345-348, 2015. doi: 10.1038/nature14282.
45. Coffelt SB, Lewis CE, Naldini L, Brown JM, Ferrara N, De Palma M. Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors. Am J Pathol 176: 1564-1576, 2010. doi: 10.2353/ajpath.2010.090786.
46. Constantinescu CS, Farooqi N, O’Brien K, Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br J Pharmacol 164: 1079-1106, 2011. doi: 10.1111/j.1476-5381.2011.01302.x.
47. Cook IH, Evans J, Maldonado-Pérez D, Critchley HO, Sales KJ, Jabbour HN. Prokineticin-1 (PROK1) modulates interleukin (IL)-11 expression via prokineticin receptor 1 (PROKR1) and the calcineurin/NFAT signalling pathway. Mol Hum Reprod 16: 158-169, 2010. doi: 10.1093/molehr/gap084.
48. Costigan M, Scholz J, Woolf CJ. Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci 32: 1-32, 2009. doi: 10.1146/annurev.neuro.051508.135531.
49. Cottrell GT, Zhou QY, Ferguson AV. Prokineticin 2 modulates the excitability of subfornical organ neurons. J Neurosci 24: 2375-2379, 2004. doi: 10.1523/JNEUROSCI.5187-03.2004.
50. Coussens LM, Werb Z. Inflammation and cancer. Nature 420: 860-867, 2002. doi: 10.1038/nature01322.
51. Curtis VF, Wang H, Yang P, McLendon RE, Li X, Zhou QY, Wang XF. A PK2/Bv8/ PROK2 antagonist suppresses tumorigenic processes by inhibiting angiogenesis in glioma and blocking myeloid cell infiltration in pancreatic cancer. PLoS One 8: e54916, 2013. doi: 10.1371/journal.pone.0054916.
52. De Felice M, Melchiorri P, Ossipov MH, Vanderah TW, Porreca F, Negri L. Mechanisms of Bv8-induced biphasic hyperalgesia: increased excitatory transmitter release and expression. Neurosci Lett 521: 40-45, 2012. doi: 10.1016/j.neulet.2012.05.055.
53. De Novellis V, Negri L, Lattanzi R, Rossi F, Palazzo E, Marabese I, Giannini E, Vita D, Melchiorri P, Maione S. The prokineticin receptor agonist Bv8 increases GABA release in the periaqueductal grey and modifies RVM cell activities and thermoceptive reflexes in the rat. Eur J Neurosci 26: 3068-3078, 2007. doi: 10.1111/j.1460-9568.2007.05910.x.
54. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 58: 49-59, 2009. doi: 10.1007/s00262-008-0523-4.
55. Dodé C, Rondard P. PROK2/PROKR2 Signaling and Kallmann Syndrome. Front Endocrinol (Lausanne) 4: 19, 2013.
56. Dodé C, Teixeira L, Levilliers J, Fouveaut C, Bouchard P, Kottler ML, Lespinasse J, Lienhardt-Roussie A, Mathieu M, Moerman A, Morgan G, Murat A, Toublanc JE, Wolczynski S, Delpech M, Petit C, Young J, Hardelin JP. Kallmann syndrome: mutations in the genes encoding prokineticin-2 and prokineticin receptor-2. PLoS Genet 2: e175, 2006. doi: 10.1371/journal.pgen.0020175.
57. Dormishian M, Turkeri G, Urayama K, Nguyen TL, Boulberdaa M, Messaddeq N, Renault G, Henrion D, Nebigil CG. Prokineticin receptor-1 is a new regulator of endothelial insulin uptake and capillary formation to control insulin sensitivity and cardiovascular and kidney functions. J Am Heart Assoc 2: e000411, 2013. doi: 10.1161/JAHA.113.000411.
58. Dorsch M, Qiu Y, Soler D, Frank N, Duong T, Goodearl A, O’Neil S, Lora J, Fraser CC. PK1/EG-VEGF induces monocyte differentiation and activation. J Leukoc Biol 78: 426-434, 2005. doi: 10.1189/jlb.0205061.
59. Dourron NE, Williams DB. Prevention and treatment of ovarian hyperstimulation syndrome. Semin Reprod Endocrinol 14: 355-365, 1996. doi: 10.1055/s-2008-1067980.
60. Dragneva G, Korpisalo P, Ylä-Herttuala S. Promoting blood vessel growth in ischemic diseases: challenges in translating preclinical potential into clinical success. Dis Model Mech 6: 312-322, 2013. doi: 10.1242/dmm.010413.
61. Dunand C, Hoffmann P, Sapin V, Blanchon L, Salomon A, Sergent F, Benharouga M, Sabra S, Guibourdenche J, Lye SJ, Feige JJ, Alfaidy N. Endocrine gland-derived endothelial growth factor (EG-VEGF) is a potential novel regulator of human parturition. Biol Reprod 91: 73, 2014. doi: 10.1095/biolreprod.114.119990.
62. Eddie SL, Childs AJ, Kinnell HL, Brown P, Jabbour HN, Anderson RA. Prokineticin Ligands and Receptors Are Expressed in the Human Fetal Ovary and Regulate Germ Cell Expression of COX2. J Clin Endocrinol Metab 100: E1197-E1205, 2015. doi: 10.1210/jc.2015-2330.
63. Evans J, Catalano RD, Morgan K, Critchley HO, Millar RP, Jabbour HN. Prokineticin 1 signaling and gene regulation in early human pregnancy. Endocrinology 149: 2877-2887, 2008. doi: 10.1210/en.2007-1633.
64. Falk S, Dickenson AH. Pain and nociception: mechanisms of cancer-induced bone pain. J Clin Oncol 32: 1647-1654, 2014. doi: 10.1200/JCO.2013.51.7219.
65. Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 21: 21-26, 2010. doi: 10.1016/j.cytogfr.2009.11.003.
66. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611, 2004. doi: 10.1210/er.2003-0027.
67. Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov 15: 385-403, 2016. doi: 10.1038/nrd.2015.17.
68. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O’Shea KS, Powell-Braxton L, Hillan KJ, Moore MW. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439-442, 1996. doi: 10.1038/380439a0.
69. Ferrara N, Frantz G, LeCouter J, Dillard-Telm L, Pham T, Draksharapu A, Giordano T, Peale F. Differential expression of the angiogenic factor genes vascular endothelial growth factor (VEGF) and endocrine gland-derived VEGF in normal and polycystic human ovaries. Am J Pathol 162: 1881-1893, 2003. doi: 10.1016/S0002-9440(10)64322-2.
70. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 9: 669-676, 2003. doi: 10.1038/nm0603-669.
71. Ferrara N, LeCouter J, Lin R, Peale F. EG-VEGF and Bv8: a novel family of tissuerestricted angiogenic factors. Biochim Biophys Acta 1654: 69-78, 2004.
72. Franchi S, Giannini E, Lattuada D, Lattanzi R, Tian H, Melchiorri P, Negri L, Panerai AE, Sacerdote P. The prokineticin receptor agonist Bv8 decreases IL-10 and IL-4 production in mice splenocytes by activating prokineticin receptor-1. BMC Immunol 9: 60, 2008. doi: 10.1186/1471-2172-9-60.
73. Fraser HM, Bell J, Wilson H, Taylor PD, Morgan K, Anderson RA, Duncan WC. Localization and quantification of cyclic changes in the expression of endocrine gland vascular endothelial growth factor in the human corpus luteum. J Clin Endocrinol Metab 90: 427-434, 2005. doi: 10.1210/jc.2004-0843.
74. Fry M, Cottrell GT, Ferguson AV. Prokineticin 2 influences subfornical organ neurons through regulation of MAP kinase and the modulation of sodium channels. Am J Physiol Regul Integr Comp Physiol 295: R848-R856, 2008. doi: 10.1152/ajpregu.00779.2007.
75. Gabrilovich DI. Myeloid-Derived Suppressor Cells. Cancer Immunol Res 5: 3-8, 2017. doi: 10.1158/2326-6066.CIR-16-0297.
76. Galer BS, Gianas A, Jensen MP. Painful diabetic polyneuropathy: epidemiology, pain description, and quality of life. Diabetes Res Clin Pract 47: 123-128, 2000. doi: 10.1016/S0168-8227(99)00112-6.
77. Gao MZ, Zhao XM, Lin Y, Sun ZG, Zhang HQ. Effects of EG-VEGF, VEGF and TGF-_1 on pregnancy outcome in patients undergoing IVF-ET treatment. J Assist Reprod Genet 29: 1091-1096, 2012. doi: 10.1007/s10815-012-9833-8.
78. Gao MZ, Zhao XM, Sun ZG, Hong Y, Zhao LW, Zhang HQ. Endocrine gland-derived vascular endothelial growth factor concentrations in follicular fluid and serum may predict ovarian hyperstimulation syndrome in women undergoing controlled ovarian hyperstimulation. Fertil Steril 95: 673-678, 2011. doi: 10.1016/j.fertnstert.2010.09.044.
79. Gao YJ, Ji RR. Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. Pharmacol Ther 126: 56-68, 2010. doi: 10.1016/j.pharmthera.2010.01.002.
80. Gardiner JV, Bataveljic A, Patel NA, Bewick GA, Roy D, Campbell D, Greenwood HC, Murphy KG, Hameed S, Jethwa PH, Ebling FJ, Vickers SP, Cheetham S, Ghatei MA, Bloom SR, Dhillo WS. Prokineticin 2 is a hypothalamic neuropeptide that potently inhibits food intake. Diabetes 59: 397-406, 2010. doi: 10.2337/db09-1198.
81. Garlanda C, Parravicini C, Sironi M, De Rossi M, Wainstok de Calmanovici R, Carozzi F, Bussolino F, Colotta F, Mantovani A, Vecchi A. Progressive growth in immunodeficient mice and host cell recruitment by mouse endothelial cells transformed by polyoma middle-sized T antigen: implications for the pathogenesis of opportunistic vascular tumors. Proc Natl Acad Sci USA 91: 7291-7295, 1994. doi: 10.1073/pnas.91.15.7291.
82. Gasser A, Brogi S, Urayama K, Nishi T, Kurose H, Tafi A, Ribeiro N, Désaubry L, Nebigil CG. Discovery and cardioprotective effects of the first non-Peptide agonists of the G protein-coupled prokineticin receptor-1. PLoS One 10: e0121027, 2015. doi: 10.1371/journal.pone.0121027.
83. Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G, Hong K, Marsters JC, Ferrara N. VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417: 954-958, 2002. doi: 10.1038/nature00821.
84. Giannini E, Lattanzi R, Nicotra A, Campese AF, Grazioli P, Screpanti I, Balboni G, Salvadori S, Sacerdote P, Negri L. The chemokine Bv8/prokineticin 2 is up-regulated in inflammatory granulocytes and modulates inflammatory pain. Proc Natl Acad Sci USA 106: 14646-14651, 2009. doi: 10.1073/pnas.0903720106.
85. Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature 391: 357-362, 1998. doi: 10.1038/34848.
86. Goi T, Nakazawa T, Hirono Y, Yamaguchi A. Prokineticin 1 expression in gastrointestinal tumors. Anticancer Res 33: 5311-5315, 2013.
87. Gordon R, Neal ML, Luo J, Langley MR, Harischandra DS, Panicker N, Charli A, Jin H, Anantharam V, Woodruff TM, Zhou QY, Kanthasamy AG, Kanthasamy A. Prokineticin-2 upregulation during neuronal injury mediates a compensatory protective response against dopaminergic neuronal degeneration. Nat Commun 7: 12932, 2016. doi: 10.1038/ncomms12932.
88. Goverman J. Autoimmune T cell responses in the central nervous system. Nat Rev Immunol 9: 393-407, 2009. doi: 10.1038/nri2550.
89. Granger JM, Kontoyiannis DP. Etiology and outcome of extreme leukocytosis in 758 nonhematologic cancer patients: a retrospective, single-institution study. Cancer 115: 3919-3923, 2009. doi: 10.1002/cncr.24480.
90. Guida F, Luongo L, Marmo F, Romano R, Iannotta M, Napolitano F, Belardo C, Marabese I, D’Aniello A, De Gregorio D, Rossi F, Piscitelli F, Lattanzi R, de Bartolomeis A, Usiello A, Di Marzo V, de Novellis V, Maione S. Palmitoylethanolamide reduces pain-related behaviors and restores glutamatergic synapses homeostasis in the medial prefrontal cortex of neuropathic mice. Mol Brain 8: 47, 2015. doi: 10.1186/s13041-015-0139-5.
91. Guilini C, Urayama K, Turkeri G, Dedeoglu DB, Kurose H, Messaddeq N, Nebigil CG. Divergent roles of prokineticin receptors in the endothelial cells: angiogenesis and fenestration. Am J Physiol Heart Circ Physiol 298: H844-H852, 2010. doi: 10.1152/ajpheart.00898.2009.
92. Han BY, Li LL, Wang CZ, Guo QH, Lv ZH, Mu YM, Dou JT. Correlation between Pituitary Stalk Interruption Syndrome and Prokineticin Receptor 2 and Prokineticin 2 Mutations. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 38: 37-41, 2016.
93. Hanahan D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315: 115-122, 1985. doi: 10.1038/315115a0.
94. Hang LH, Luo H, Li SN, Shu WW, Chen Z, Chen YF, Yuan JF, Shi LL, Shao DH. Involvement of Spinal Bv8/Prokineticin 2 in a Rat Model of Cancer-Induced Bone Pain. Basic Clin Pharmacol Toxicol 117: 180-185, 2015. doi: 10.1111/bcpt.12386.
95. Hasnis E, Alishekevitz D, Gingis-Veltski S, Bril R, Fremder E, Voloshin T, Raviv Z, Karban A, Shaked Y. Anti-Bv8 antibody and metronomic gemcitabine improve pancreatic adenocarcinoma treatment outcome following weekly gemcitabine therapy. Neoplasia 16: 501-510, 2014. doi: 10.1016/j.neo.2014.05.011.
96. Hastings MH. Circadian rhythms: a gut feeling for time. Nature 417: 391-392, 2002. doi: 10.1038/417391a.
97. Heck D, Wortmann S, Kraus L, Ronchi CL, Sinnott RO, Fassnacht M, Sbiera S. Role of Endocrine Gland-Derived Vascular Endothelial Growth Factor (EG-VEGF) and Its Receptors in Adrenocortical Tumors. Horm Cancer 6: 225-236, 2015. doi: 10.1007/s12672-015-0236-z.
98. Hodgen GD. The dominant ovarian follicle. Fertil Steril 38: 281-300, 1982.
99. Hoffmann P, Feige JJ, Alfaidy N. Expression and oxygen regulation of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 and its receptors in human placenta during early pregnancy. Endocrinology 147: 1675-1684, 2006. doi: 10.1210/en.2005-0912.
100. Hoffmann P, Feige JJ, Alfaidy N. Placental expression of EG-VEGF and its receptors PKR1 (prokineticin receptor-1) and PKR2 throughout mouse gestation. Placenta 28: 1049-1058, 2007. doi: 10.1016/j.placenta.2007.03.008.
101. Hoffmann P, Saoudi Y, Benharouga M, Graham CH, Schaal JP, Mazouni C, Feige JJ, Alfaidy N. Role of EG-VEGF in human placentation: physiological and pathological implications. J Cell Mol Med 13, 8B: 2224-2235, 2009. doi: 10.1111/j.1582-4934.2008.00554.x.
102. Hoffmann T, Negri L, Maftei D, Lattanzi R, Reeh PW. The prokineticin Bv8 sensitizes cutaneous terminals of female mice to heat. Eur J Pain 20: 1326-1334, 2016. doi: 10.1002/ejp.857.
103. Hu WP, Li JD, Zhang C, Boehmer L, Siegel JM, Zhou QY. Altered circadian and homeostatic sleep regulation in prokineticin 2-deficient mice. Sleep 30: 247-256, 2007.
104. Hu WP, Zhang C, Li JD, Luo ZD, Amadesi S, Bunnett N, Zhou QY. Impaired pain sensation in mice lacking prokineticin 2. Mol Pain 2: 35, 2006. doi: 10.1186/1744-8069-2-35.
105. Ingves MV, Ferguson AV. Prokineticin 2 modulates the excitability of area postrema neurons in vitro in the rat. Am J Physiol Regul Integr Comp Physiol 298: R617-R626, 2010. doi: 10.1152/ajpregu.00620.2009.
106. Ito H, Noda K, Yoshida K, Otani K, Yoshiga M, Oto Y, Saito S, Kurosaka D. Prokineticin 2 antagonist, PKRA7 suppresses arthritis in mice with collagen-induced arthritis. BMC Musculoskelet Disord 17: 387, 2016. doi: 10.1186/s12891-016-1243-0.
107. Iwasa T, Matsuzaki T, Tungalagsuvd A, Munkhzaya M, Kawami T, Yamasaki M, Murakami M, Kato T, Kuwahara A, Yasui T, Irahara M. Changes in the responsiveness of hypothalamic PK2 and PKR1 gene expression to fasting in developing male rats. Int J Dev Neurosci 38: 87-90, 2014. doi: 10.1016/j.ijdevneu.2014.08.004.
108. Jilek A, Engel E, Beier D, Lepperdinger G. Murine Bv8 gene maps near a synteny breakpoint of mouse chromosome 6 and human 3p21. Gene 256: 189-195, 2000. doi: 10.1016/S0378-1119(00)00355-3.
109. Joubert FJ, Strydom DJ. Snake venom. The amino acid sequence of protein A from Dendroaspis polylepis polylepis (black mamba) venom. Hoppe Seylers Z Physiol Chem 361: 1787-1794, 1980. doi: 10.1515/bchm2.1980.361.2.1787.
110. Kaser A, Winklmayr M, Lepperdinger G, Kreil G. The AVIT protein family. Secreted cysteine-rich vertebrate proteins with diverse functions. EMBO Rep 4: 469-473, 2003. doi: 10.1038/sj.embor.embor830.
111. Kemmann E, Tavakoli F, Shelden RM, Jones JR. Induction of ovulation with menotropins in women with polycystic ovary syndrome. Am J Obstet Gynecol 141: 58-64, 1981. doi: 10.1016/0002-9378(81)90675-X.
112. Keramidas M, Faudot C, Cibiel A, Feige JJ, Thomas M. Mitogenic functions of endocrine gland-derived vascular endothelial growth factor and Bombina variegata 8 on steroidogenic adrenocortical cells. J Endocrinol 196: 473-482, 2008. doi: 10.1677/JOE-07-0255.
113. Khusal KG, Tonelli RR, Mattos EC, Soares CO, Di Genova BM, Juliano MA, Urias U, Colli W, Alves MJ. Prokineticin receptor identified by phage display is an entry receptor for Trypanosoma cruzi into mammalian cells. Parasitol Res 114: 155-165, 2015. doi: 10.1007/s00436-014-4172-6.
114. Kishi T, Kitajima T, Tsunoka T, Okumura T, Ikeda M, Okochi T, Kinoshita Y, Kawashima K, Yamanouchi Y, Ozaki N, Iwata N. Possible association of prokineticin 2 receptor gene (PROKR2) with mood disorders in the Japanese population. Neuromolecular Med 11: 114-122, 2009. doi: 10.1007/s12017-009-8067-0.
115. Kisliouk T, Friedman A, Klipper E, Zhou QY, Schams D, Alfaidy N, Meidan R. Expression pattern of prokineticin 1 and its receptors in bovine ovaries during the estrous cycle: involvement in corpus luteum regression and follicular atresia. Biol Reprod 76: 749-758, 2007. doi: 10.1095/biolreprod.106.054734.
116. Kisliouk T, Podlovni H, Meidan R. Unique expression and regulatory mechanisms of EG-VEGF/prokineticin-1 and its receptors in the corpus luteum. Ann Anat 187: 529-537, 2005. doi: 10.1016/j.aanat.2005.07.005.
117. Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong W-L, Pope RM, Ferrara N. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 152: 4149-4156, 1994.
118. Kowanetz M, Wu X, Lee J, Tan M, Hagenbeek T, Qu X, Yu L, Ross J, Korsisaari N, Cao T, Bou-Reslan H, Kallop D, Weimer R, Ludlam MJ, Kaminker JS, Modrusan Z, van Bruggen N, Peale FV, Carano R, Meng YG, Ferrara N. Granulocyte-colony stimulating factor promotes lung metastasis through mobilization of Ly6G_Ly6C_granulocytes. Proc Natl Acad Sci USA 107: 21248-21255, 2010. doi: 10.1073/pnas.1015855107.
119. Koyama Y, Kiyo-oka M, Osakada M, Horiguchi N, Shintani N, Ago Y, Kakuda M, Baba A, Matsuda T. Expression of prokineticin receptors in mouse cultured astrocytes and involvement in cell proliferation. Brain Res 1112: 65-69, 2006. doi: 10.1016/j.brainres.2006.07.013.
120. Kubo A, Sujino M, Masumoto KH, Fujioka A, Terashima T, Shigeyoshi Y, Nagano M. Profiles of Periglomerular Cells in the Olfactory Bulb of Prokineticin Type 2 Receptordeficient Mice. Acta Histochem Cytochem 50: 95-104, 2017. doi: 10.1267/ahc.17001.
121. Kurosaka D, Noda K, Yoshida K, Furuya K, Ukichi T, Takahashi E, Yanagimachi M, Kingetsu I, Saito S, Yamada A. Elevation of Bombina variegata peptide 8 in mice with collagen-induced arthritis. BMC Musculoskelet Disord 10: 45, 2009. doi: 10.1186/1471-2474-10-45.
122. Lambert CM, Machida KK, Smale L, Nunez AA, Weaver DR. Analysis of the prokineticin 2 system in a diurnal rodent, the unstriped Nile grass rat (Arvicanthis niloticus). J Biol Rhythms 20: 206-218, 2005. doi: 10.1177/0748730405275135.
123. Landucci E, Lattanzi R, Gerace E, Scartabelli T, Balboni G, Negri L, Pellegrini-Giampietro DE. Prokineticins are neuroprotective in models of cerebral ischemia and ischemic tolerance in vitro. Neuropharmacology 108: 39-48, 2016. doi: 10.1016/j.neuropharm.2016.04.043.
124. Lattanzi R, Sacerdote P, Franchi S, Canestrelli M, Miele R, Barra D, Visentin S, DeNuccio C, Porreca F, De Felice M, Guida F, Luongo L, de Novellis V, Maione S, Negri L. Pharmacological activity of a Bv8 analogue modified in position 24. Br J Pharmacol 166: 950-963, 2012. doi: 10.1111/j.1476-5381.2011.01797.x.
125. Lau ST, Hansford LM, Chan WK, Chan GC, Wan TS, Wong KK, Kaplan DR, Tam PK, Ngan ES. Prokineticin signaling is required for the maintenance of a de novo population of c-KIT_ cells to sustain neuroblastoma progression. Oncogene 34: 1019-1034, 2015. doi: 10.1038/onc.2014.24.
126. LeCouter J, Ferrara N. EG-VEGF and Bv8. a novel family of tissue-selective mediators of angiogenesis, endothelial phenotype, and function. Trends Cardiovasc Med 13: 276-282, 2003. doi: 10.1016/S1050-1738(03)00110-5.
127. LeCouter J, Kowalski J, Foster J, Hass P, Zhang Z, Dillard-Telm L, Frantz G, Rangell L, DeGuzman L, Keller G-A, Peale F, Gurney A, Hillan KJ, Ferrara N. Identification of an angiogenic mitogen selective for endocrine gland endothelium. Nature 412: 877-884, 2001. doi: 10.1038/35091000.
128. LeCouter J, Lin R, Ferrara N. Endocrine gland-derived VEGF and the emerging hypothesis of organ-specific regulation of angiogenesis. Nat Med 8: 913-917, 2002. doi: 10.1038/nm0902-913.
129. LeCouter J, Lin R, Frantz G, Zhang Z, Hillan K, Ferrara N. Mouse endocrine glandderived vascular endothelial growth factor: a distinct expression pattern from its human ortholog suggests different roles as a regulator of organ-specific angiogenesis. Endocrinology 144: 2606-2616, 2003. doi: 10.1210/en.2002-0146.
130. LeCouter J, Lin R, Tejada M, Frantz G, Peale F, Hillan KJ, Ferrara N. The endocrinegland- derived VEGF homologue Bv8 promotes angiogenesis in the testis: localization of Bv8 receptors to endothelial cells. Proc Natl Acad Sci USA 100: 2685-2690, 2003. doi: 10.1073/pnas.0337667100.
131. LeCouter J, Zlot C, Tejada M, Peale F, Ferrara N. Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. Proc Natl Acad Sci USA 101: 16813-16818, 2004. doi: 10.1073/pnas.0407697101.
132. Levit A, Yarnitzky T, Wiener A, Meidan R, Niv MY. Modeling of human prokineticin receptors: interactions with novel small-molecule binders and potential off-target drugs. PLoS One 6: e27990, 2011. doi: 10.1371/journal.pone.0027990.
133. Li JD, Hu WP, Boehmer L, Cheng MY, Lee AG, Jilek A, Siegel JM, Zhou QY. Attenuated circadian rhythms in mice lacking the prokineticin 2 gene. J Neurosci 26: 11615-11623, 2006. doi: 10.1523/JNEUROSCI.3679-06.2006.
134. Li JD, Hu WP, Zhou QY. The circadian output signals from the suprachiasmatic nuclei. Prog Brain Res 199: 119-127, 2012. doi: 10.1016/B978-0-444-59427-3.00028-9.
135. Li JD, Hu WP, Zhou QY. Disruption of the circadian output molecule prokineticin 2 results in anxiolytic and antidepressant-like effects in mice. Neuropsychopharmacology 34: 367-373, 2009. doi: 10.1038/npp.2008.61.
136. Li M, Bullock CM, Knauer DJ, Ehlert FJ, Zhou QY. Identification of two prokineticin cDNAs: recombinant proteins potently contract gastrointestinal smooth muscle. Mol Pharmacol 59: 692-698, 2001. doi: 10.1124/mol.59.4.692.
137. Liang W, Ferrara N. The Complex Role of Neutrophils in Tumor Angiogenesis and Metastasis. Cancer Immunol Res 4: 83-91, 2016. doi: 10.1158/2326-6066.CIR-15-0313.
138. Lin DC, Bullock CM, Ehlert FJ, Chen JL, Tian H, Zhou QY. Identification and molecular characterization of two closely related G protein-coupled receptors activated by prokineticins/endocrine gland vascular endothelial growth factor. J Biol Chem 277: 19276-19280, 2002. doi: 10.1074/jbc.M202139200.
139. Lin R, LeCouter J, Kowalski J, Ferrara N. Characterization of endocrine gland-derived vascular endothelial growth factor signaling in adrenal cortex capillary endothelial cells. J Biol Chem 277: 8724-8729, 2002. doi: 10.1074/jbc.M110594200.
140. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117: 1175-1183, 2007. doi: 10.1172/JCI31537.
141. Lin X, Kim YA, Lee BL, Söderhäll K, Söderhäll I. Identification and properties of a receptor for the invertebrate cytokine astakine, involved in hematopoiesis. Exp Cell Res 315: 1171-1180, 2009. doi: 10.1016/j.yexcr.2009.01.001.
142. Lu R, Kujawski M, Pan H, Shively JE. Tumor angiogenesis mediated by myeloid cells is negatively regulated by CEACAM1. Cancer Res 72: 2239-2250, 2012. doi: 10.1158/0008-5472.CAN-11-3016.
143. Maftei D, Marconi V, Florenzano F, Giancotti LA, Castelli M, Moretti S, Borsani E, Rodella LF, Balboni G, Luongo L, Maione S, Sacerdote P, Negri L, Lattanzi R. Controlling the activation of the Bv8/prokineticin system reduces neuroinflammation and abolishes thermal and tactile hyperalgesia in neuropathic animals. Br J Pharmacol 171: 4850-4865, 2014. doi: 10.1111/bph.12793.
144. Maldonado-Pérez D, Evans J, Denison F, Millar RP, Jabbour HN. Potential roles of the prokineticins in reproduction. Trends Endocrinol Metab 18: 66-72, 2007. doi: 10.1016/j.tem.2006.12.002.
145. Mansour HA, Wood J, Logue T, Chowdari KV, Dayal M, Kupfer DJ, Monk TH, Devlin B, Nimgaonkar VL. Association study of eight circadian genes with bipolar I disorder, schizoaffective disorder and schizophrenia. Genes Brain Behav 5: 150-157, 2006. doi: 10.1111/j.1601-183X.2005.00147.x.
146. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 371: 771-783, 2008. doi: 10.1016/S0140-6736(08)60241-X.
147. Marigo I, Dolcetti L, Serafini P, Zanovello P, Bronte V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222: 162-179, 2008. doi: 10.1111/j.1600-065X.2008.00602.x.
148. Marsango S, Bonaccorsi di Patti MC, Barra D, Miele R. Evidence that prokineticin receptor 2 exists as a dimer in vivo. Cell Mol Life Sci 68: 2919-2929, 2011. doi: 10.1007/s00018-010-0601-6.
149. Martin C, Balasubramanian R, Dwyer AA, Au MG, Sidis Y, Kaiser UB, Seminara SB, Pitteloud N, Zhou QY, Crowley WF Jr. The role of the prokineticin 2 pathway in human reproduction: evidence from the study of human and murine gene mutations. Endocr Rev 32: 225-246, 2011. doi: 10.1210/er.2010-0007.
150. Martucci C, Franchi S, Giannini E, Tian H, Melchiorri P, Negri L, Sacerdote P. Bv8, the amphibian homologue of the mammalian prokineticins, induces a proinflammatory phenotype of mouse macrophages. Br J Pharmacol 147: 225-234, 2006. doi: 10.1038/sj.bjp.0706467.
151. Masuda Y, Takatsu Y, Terao Y, Kumano S, Ishibashi Y, Suenaga M, Abe M, Fukusumi S, Watanabe T, Shintani Y, Yamada T, Hinuma S, Inatomi N, Ohtaki T, Onda H, Fujino M. Isolation and identification of EG-VEGF/prokineticins as cognate ligands for two orphan G-protein-coupled receptors. Biochem Biophys Res Commun 293: 396-402, 2002. doi: 10.1016/S0006-291X(02)00239-5.
152. Matsumoto S, Yamazaki C, Masumoto KH, Nagano M, Naito M, Soga T, Hiyama H, Matsumoto M, Takasaki J, Kamohara M, Matsuo A, Ishii H, Kobori M, Katoh M, Matsushime H, Furuichi K, Shigeyoshi Y. Abnormal development of the olfactory bulb and reproductive system in mice lacking prokineticin receptor PKR2. Proc Natl Acad Sci USA 103: 4140-4145, 2006. doi: 10.1073/pnas.0508881103.
153. McCabe MJ, Gaston-Massuet C, Gregory LC, Alatzoglou KS, Tziaferi V, Sbai O, Rondard P, Masumoto KH, Nagano M, Shigeyoshi Y, Pfeifer M, Hulse T, Buchanan CR, Pitteloud N, Martinez-Barbera JP, Dattani MT. Variations in PROKR2, but not PROK2, are associated with hypopituitarism and septo-optic dysplasia. J Clin Endocrinol Metab 98: E547-E557, 2013. doi: 10.1210/jc.2012-3067.
154. McCoach CE, Rogers JG, Dwyre DM, Jonas BA. Paraneoplastic Leukemoid Reaction as a Marker of Tumor Progression in Non-Small Cell Lung Cancer. Cancer Treat Commun 4: 15-18, 2015. doi: 10.1016/j.ctrc.2015.03.003.
155. Melchiorri D, Bruno V, Besong G, Ngomba RT, Cuomo L, De Blasi A, Copani A, Moschella C, Storto M, Nicoletti F, Lepperdinger G, Passarelli F. The mammalian homologue of the novel peptide Bv8 is expressed in the central nervous system and supports neuronal survival by activating the MAP kinase/PI-3-kinase pathways. Eur J Neurosci 13: 1694-1702, 2001. doi: 10.1046/j.1460-9568.2001.01549.x.
156. Merrill JA. Ovarian hilus cells. Am J Obstet Gynecol 78: 1258-1271, 1959. doi: 10.1016/0002-9378(59)90588-5.
157. Miotla J, Maciewicz R, Kendrew J, Feldmann M, Paleolog E. Treatment with soluble VEGF receptor reduces disease severity in murine collagen-induced arthritis. Lab Invest 80: 1195-1205, 2000. doi: 10.1038/labinvest.3780127.
158. Mollay C, Wechselberger C, Mignogna G, Negri L, Melchiorri P, Barra D, Kreil G. Bv8, a small protein from frog skin and its homologue from snake venom induce hyperalgesia in rats. Eur J Pharmacol 374: 189-196, 1999. doi: 10.1016/S0014-2999(99)00229-0.
159. Monnier C, Dodé C, Fabre L, Teixeira L, Labesse G, Pin JP, Hardelin JP, Rondard P. PROKR2 missense mutations associated with Kallmann syndrome impair receptor signalling activity. Hum Mol Genet 18: 75-81, 2009. doi: 10.1093/hmg/ddn318.
160. Monnier J, Quillien V, Piquet-Pellorce C, Leberre C, Preisser L, Gascan H, Samson M. Prokineticin 1 induces CCL4, CXCL1 and CXCL8 in human monocytes but not in macrophages and dendritic cells. Eur Cytokine Netw 19: 166-175, 2008.
161. Monnier J, Samson M. Cytokine properties of prokineticins. FEBS J 275: 4014-4021, 2008. doi: 10.1111/j.1742-4658.2008.06559.x.
162. Nebigil CG. Prokineticin receptors in cardiovascular function: foe or friend? Trends Cardiovasc Med 19: 55-60, 2009. doi: 10.1016/j.tcm.2009.04.007.
163. Negri L, Lattanzi R. Bv8/PK2 and prokineticin receptors: a druggable pronociceptive system. Curr Opin Pharmacol 12: 62-66, 2012. doi: 10.1016/j.coph.2011.10.023.
164. Negri L, Lattanzi R, Giannini E, Canestrelli M, Nicotra A, Melchiorri P. Bv8/Prokineticins and their Receptors: A New Pronociceptive System. Int Rev Neurobiol 85: 145-157, 2009. doi: 10.1016/S0074-7742(09)85011-3.
165. Negri L, Lattanzi R, Giannini E, Colucci M, Margheriti F, Melchiorri P, Vellani V, Tian H, De Felice M, Porreca F. Impaired nociception and inflammatory pain sensation in mice lacking the prokineticin receptor PKR1: focus on interaction between PKR1 and the capsaicin receptor TRPV1 in pain behavior. J Neurosci 26: 6716-6727, 2006. doi: 10.1523/JNEUROSCI.5403-05.2006.
166. Negri L, Lattanzi R, Giannini E, Colucci MA, Mignogna G, Barra D, Grohovaz F, Codazzi F, Kaiser A, Kreil G, Melchiorri P. Biological activities of Bv8 analogues. Br J Pharmacol 146: 625-632, 2005. doi: 10.1038/sj.bjp.0706376.
167. Negri L, Lattanzi R, Giannini E, De Felice M, Colucci A, Melchiorri P. Bv8, the amphibian homologue of the mammalian prokineticins, modulates ingestive behaviour in rats. Br J Pharmacol 142: 181-191, 2004. doi: 10.1038/sj.bjp.0705686.
168. Negri L, Lattanzi R, Giannini E, Melchiorri P. Bv8/Prokineticin proteins and their receptors. Life Sci 81: 1103-1116, 2007. doi: 10.1016/j.lfs.2007.08.011.
169. Negri L, Lattanzi R, Giannini E, Melchiorri P. Modulators of pain: Bv8 and prokineticins. Curr Neuropharmacol 4: 207-215, 2006. doi: 10.2174/157015906778019518.
170. Negri L, Lattanzi R, Giannini E, Metere A, Colucci M, Barra D, Kreil G, Melchiorri P. Nociceptive sensitization by the secretory protein Bv8. Br J Pharmacol 137: 1147-1154, 2002. doi: 10.1038/sj.bjp.0704995.
171. Ng KL, Li JD, Cheng MY, Leslie FM, Lee AG, Zhou QY. Dependence of olfactory bulb neurogenesis on prokineticin 2 signaling. Science 308: 1923-1927, 2005. doi: 10.1126/science.1112103.
172. Ngan ES, Lee KY, Sit FY, Poon HC, Chan JK, Sham MH, Lui VC, Tam PK. Prokineticin-1 modulates proliferation and differentiation of enteric neural crest cells. Biochim Biophys Acta 1773: 536-545, 2007. doi: 10.1016/j.bbamcr.2007.01.013.
173. Ngan ES, Lee KY, Yeung WS, Ngan HY, Ng EH, Ho PC. Endocrine gland-derived vascular endothelial growth factor is expressed in human peri-implantation endometrium, but not in endometrial carcinoma. Endocrinology 147: 88-95, 2006. doi: 10.1210/en.2005-0543.
174. Ngan ES, Sit FY, Lee K, Miao X, Yuan Z, Wang W, Nicholls JM, Wong KK, Garcia-Barcelo M, Lui VC, Tam PK. Implications of endocrine gland-derived vascular endothelial growth factor/prokineticin-1 signaling in human neuroblastoma progression. Clin Cancer Res 13: 868-875, 2007. doi: 10.1158/1078-0432.CCR-06-2176.
175. Ngan ES, Tam PK. Prokineticin-signaling pathway. Int J Biochem Cell Biol 40: 1679-1684, 2008. doi: 10.1016/j.biocel.2008.03.010.
176. Pan H, Shively JE. Carcinoembryonic antigen-related cell adhesion molecule-1 regulates granulopoiesis by inhibition of granulocyte colony-stimulating factor receptor. Immunity 33: 620-631, 2010. doi: 10.1016/j.immuni.2010.10.009.
177. Parker KL, Rice DA, Lala DS, Ikeda Y, Luo X, Wong M, Bakke M, Zhao L, Frigeri C, Hanley NA, Stallings N, Schimmer BP. Steroidogenic factor 1: an essential mediator of endocrine development. Recent Prog Horm Res 57: 19-36, 2002. doi: 10.1210/rp.57.1.19.
178. Parker R, Liu M, Eyre HJ, Copeland NG, Gilbert DJ, Crawford J, Sutherland GR, Jenkins NA, Herzog H. Y-receptor-like genes GPR72 and GPR73: molecular cloning, genomic organisation and assignment to human chromosome 11q21.1 and 2p14 and mouse chromosome 9 and 6. Biochim Biophys Acta 1491: 369-375, 2000. doi: 10.1016/S0167-4781(00)00023-3.
179. Pasquali D, Rossi V, Staibano S, De Rosa G, Chieffi P, Prezioso D, Mirone V, Mascolo M, Tramontano D, Bellastella A, Sinisi AA. The endocrine-gland-derived vascular endothelial growth factor (EG-VEGF)/prokineticin 1 and 2 and receptor expression in human prostate: Up-regulation of EG-VEGF/prokineticin 1 with malignancy. Endocrinology 147: 4245-4251, 2006. doi: 10.1210/en.2006-0614.
180. Peng Z, Tang Y, Luo H, Jiang F, Yang J, Sun L, Li JD. Disease-causing mutation in PKR2 receptor reveals a critical role of positive charges in the second intracellular loop for G-protein coupling and receptor trafficking. J Biol Chem 286: 16615-16622, 2011. doi: 10.1074/jbc.M111.223784.
181. Phan VT, Wu X, Cheng JH, Sheng RX, Chung AS, Zhuang G, Tran C, Song Q, Kowanetz M, Sambrone A, Tan M, Meng YG, Jackson EL, Peale FV, Junttila MR, Ferrara N. Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment. Proc Natl Acad Sci USA 110: 6079-6084, 2013. doi: 10.1073/pnas.1303302110.
182. Pitteloud N, Quinton R, Pearce S, Raivio T, Acierno J, Dwyer A, Plummer L, Hughes V, Seminara S, Cheng YZ, Li WP, Maccoll G, Eliseenkova AV, Olsen SK, Ibrahimi OA, Hayes FJ, Boepple P, Hall JE, Bouloux P, Mohammadi M, Crowley W Jr. Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J Clin Invest 117: 457-463, 2007. doi: 10.1172/JCI29884.
183. Pitteloud N, Zhang C, Pignatelli D, Li JD, Raivio T, Cole LW, Plummer L, Jacobson-Dickman EE, Mellon PL, Zhou QY, Crowley WF Jr. Loss-of-function mutation in the prokineticin 2 gene causes Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci USA 104: 17447-17452, 2007. doi: 10.1073/pnas.0707173104.
184. Prosser HM, Bradley A, Chesham JE, Ebling FJ, Hastings MH, Maywood ES. Prokineticin receptor 2 (Prokr2) is essential for the regulation of circadian behavior by the suprachiasmatic nuclei. Proc Natl Acad Sci USA 104: 648-653, 2007. doi: 10.1073/pnas.0606884104.
185. Qiu CY, Liu YQ, Qiu F, Wu J, Zhou QY, Hu WP. Prokineticin 2 potentiates acidsensing ion channel activity in rat dorsal root ganglion neurons. J Neuroinflammation 9: 108, 2012. doi: 10.1186/1742-2094-9-108.
186. Qu X, Zhuang G, Yu L, Meng G, Ferrara N. Induction of Bv8 expression by granulocyte colony-stimulating factor in CD11b_Gr1_cells: key role of Stat3 signaling. J Biol Chem 287: 19574-19584, 2012. doi: 10.1074/jbc.M111.326801.
187. Raivio T, Avbelj M, McCabe MJ, Romero CJ, Dwyer AA, Tommiska J, Sykiotis GP, Gregory LC, Diaczok D, Tziaferi V, Elting MW, Padidela R, Plummer L, Martin C, Feng B, Zhang C, Zhou QY, Chen H, Mohammadi M, Quinton R, Sidis Y, Radovick S, Dattani MT, Pitteloud N. Genetic overlap in Kallmann syndrome, combined pituitary hormone deficiency, and septo-optic dysplasia. J Clin Endocrinol Metab 97: E694-E699, 2012. doi: 10.1210/jc.2011-2938.
188. Ren C, Qiu CY, Gan X, Liu TT, Qu ZW, Rao Z, Hu WP. Prokineticin 2 facilitates mechanical allodynia induced by _,_-methylene ATP in rats. Eur J Pharmacol 767: 24-29, 2015. doi: 10.1016/j.ejphar.2015.09.047.
189. Ren P, Zhang H, Qiu F, Liu YQ, Gu H, O’Dowd DK, Zhou QY, Hu WP. Prokineticin 2 regulates the electrical activity of rat suprachiasmatic nuclei neurons. PLoS One 6: e20263, 2011. doi: 10.1371/journal.pone.0020263.
190. Reynaud R, Jayakody SA, Monnier C, Saveanu A, Bouligand J, Guedj AM, Simonin G, Lecomte P, Barlier A, Rondard P, Martinez-Barbera JP, Guiochon-Mantel A, Brue T. PROKR2 variants in multiple hypopituitarism with pituitary stalk interruption. J Clin Endocrinol Metab 97: E1068-E1073, 2012. doi: 10.1210/jc.2011-3056.
191. Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol 11: 73-91, 1995. doi: 10.1146/annurev.cb.11.110195.000445.
192. Roberts AW. G-CSF: a key regulator of neutrophil production, but that’s not all! Growth Factors 23: 33-41, 2005. doi: 10.1080/08977190500055836.
193. Ruiz-Ferrer M, Torroglosa A, Núñez-Torres R, de Agustín JC, Antiñolo G, Borrego S. Expression of PROKR1 and PROKR2 in human enteric neural precursor cells and identification of sequence variants suggest a role in HSCR. PLoS One 6: e23475, 2011. doi: 10.1371/journal.pone.0023475.
194. Samson M, Peale FV Jr, Frantz G, Rioux-Leclercq N, Rajpert-De Meyts E, Ferrara N. Human endocrine gland-derived vascular endothelial growth factor: expression early in development and in Leydig cell tumors suggests roles in normal and pathological testis angiogenesis. J Clin Endocrinol Metab 89: 4078-4088, 2004. doi: 10.1210/jc.2003-032024.
195. Sarfati J, Fouveaut C, Leroy C, Jeanpierre M, Hardelin JP, Dodé C. Greater prevalence of PROKR2 mutations in Kallmann syndrome patients from the Maghreb than in European patients. Eur J Endocrinol 169: 805-809, 2013. doi: 10.1530/EJE-13-0419.
196. Sarfati J, Guiochon-Mantel A, Rondard P, Arnulf I, Garcia-Piñero A, Wolczynski S, Brailly-Tabard S, Bidet M, Ramos-Arroyo M, Mathieu M, Lienhardt-Roussie A, Morgan G, Turki Z, Bremont C, Lespinasse J, Du Boullay H, Chabbert-Buffet N, Jacquemont S, Reach G, De Talence N, Tonella P, Conrad B, Despert F, Delobel B, Brue T, Bouvattier C, Cabrol S, Pugeat M, Murat A, Bouchard P, Hardelin JP, Dodé C, Young J. A comparative phenotypic study of kallmann syndrome patients carrying monoallelic and biallelic mutations in the prokineticin 2 or prokineticin receptor 2 genes. J Clin Endocrinol Metab 95: 659-669, 2010. doi: 10.1210/jc.2009-0843.
197. Sbai O, Monnier C, Dodé C, Pin JP, Hardelin JP, Rondard P. Biased signaling through G-protein-coupled PROKR2 receptors harboring missense mutations. FASEB J 28: 3734-3744, 2014. doi: 10.1096/fj.13-243402.
198. Schweitz H, Pacaud P, Diochot S, Moinier D, Lazdunski M. MIT(1), a black mamba toxin with a new and highly potent activity on intestinal contraction. FEBS Lett 461: 183-188, 1999. doi: 10.1016/S0014-5793(99)01459-3.
199. Schweizerhof M, Stösser S, Kurejova M, Njoo C, Gangadharan V, Agarwal N, Schmelz M, Bali KK, Michalski CW, Brugger S, Dickenson A, Simone DA, Kuner R. Hematopoietic colony-stimulating factors mediate tumor-nerve interactions and bone cancer pain. Nat Med 15: 802-807, 2009. doi: 10.1038/nm.1976.
200. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16: 53-65, 2006. doi: 10.1016/j.semcancer.2005.07.005.
201. Severini C, Lattanzi R, Maftei D, Marconi V, Ciotti MT, Petrocchi Passeri P, Florenzano F, Del Duca E, Caioli S, Zona C, Balboni G, Salvadori S, Nisticò R, Negri L. Bv8/prokineticin 2 is involved in A_-induced neurotoxicity. Sci Rep 5: 15301, 2015. doi: 10.1038/srep15301.
202. Sher D, Knebel A, Bsor T, Nesher N, Tal T, Morgenstern D, Cohen E, Fishman Y, Zlotkin E. Toxic polypeptides of the hydra-a bioinformatic approach to cnidarian allomones. Toxicon 45: 865-879, 2005. doi: 10.1016/j.toxicon.2005.02.004.
203. Shojaei F, Ferrara N. Role of the microenvironment in tumor growth and in refractoriness/ resistance to anti-angiogenic therapies. Drug Resist Updat 11: 219-230, 2008. doi: 10.1016/j.drup.2008.09.001.
204. Shojaei F, Singh M, Thompson JD, Ferrara N. Role of Bv8 in neutrophil-dependent angiogenesis in a transgenic model of cancer progression. Proc Natl Acad Sci USA 105: 2640-2645, 2008. doi: 10.1073/pnas.0712185105.
205. Shojaei F, Wu X, Malik AK, Zhong C, Baldwin ME, Schanz S, Fuh G, Gerber HP, Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b_Gr1_ myeloid cells. Nat Biotechnol 25: 911-920, 2007. doi: 10.1038/nbt1323.
206. Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, Meng YG, Ferrara N. G-CSFinitiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA 106: 6742-6747, 2009. doi: 10.1073/pnas.0902280106.
207. Shojaei F, Wu X, Zhong C, Yu L, Liang XH, Yao J, Blanchard D, Bais C, Peale FV, van Bruggen N, Ho C, Ross J, Tan M, Carano RA, Meng YG, Ferrara N. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450: 825-831, 2007. doi: 10.1038/nature06348.
208. Shojaei F, Zhong C, Wu X, Yu L, Ferrara N. Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol 18: 372-378, 2008. doi: 10.1016/j.tcb.2008.06.003.
209. Sinisi AA, Asci R, Bellastella G, Maione L, Esposito D, Elefante A, De Bellis A, Bellastella A, Iolascon A. Homozygous mutation in the prokineticin-receptor2 gene (Val274Asp) presenting as reversible Kallmann syndrome and persistent oligozoospermia: case report. Hum Reprod 23: 2380-2384, 2008. doi: 10.1093/humrep/den247.
210. Söderhäll I, Kim YA, Jiravanichpaisal P, Lee SY, Söderhäll K. An ancient role for a prokineticin domain in invertebrate hematopoiesis. J Immunol 174: 6153-6160, 2005. doi: 10.4049/jimmunol.174.10.6153.
211. Soga T, Matsumoto S, Oda T, Saito T, Hiyama H, Takasaki J, Kamohara M, Ohishi T, Matsushime H, Furuichi K. Molecular cloning and characterization of prokineticin receptors. Biochim Biophys Acta 1579: 173-179, 2002. doi: 10.1016/S0167-4781(02)00546-8.
212. Song J, Li J, Liu HD, Liu W, Feng Y, Zhou XT, Li JD. Snapin interacts with G-protein coupled receptor PKR2. Biochem Biophys Res Commun 469: 501-506, 2016. doi: 10.1016/j.bbrc.2015.12.023.
213. Sposini S, Caltabiano G, Hanyaloglu AC, Miele R. Identification of transmembrane domains that regulate spatial arrangements and activity of prokineticin receptor 2 dimers. Mol Cell Endocrinol 399: 362-372, 2015. doi: 10.1016/j.mce.2014.10.024.
214. Springael JY, Urizar E, Parmentier M. Dimerization of chemokine receptors and its functional consequences. Cytokine Growth Factor Rev 16: 611-623, 2005. doi: 10.1016/j.cytogfr.2005.05.005.
215. Steinman L. Immunology of relapse and remission in multiple sclerosis. Annu Rev Immunol 32: 257-281, 2014. doi: 10.1146/annurev-immunol-032713-120227.
216. Sternberg WH. The morphology, androgenic function, hyperplasia, and tumors of the human ovarian hilus cells. Am J Pathol 25: 493-521, 1949.
217. Strauss JF, Barbieri RL. Yen & Jaffe’s Reproductive Endocrinology (7th ed.). Philadelphia, PA: Saunders, 2013.
218. Strydom DJ. Snake venom toxins. Purification and properties of low-molecularweight polypeptides of Dendroaspis polylepis polylepis (black mamba) venom. Eur J Biochem 69: 169-176, 1976. doi: 10.1111/j.1432-1033.1976.tb10870.x.
219. Su MT, Lin SH, Chen YC, Kuo PL. Gene-gene interactions and risk of recurrent miscarriages in carriers of endocrine gland-derived vascular endothelial growth factor and prokineticin receptor polymorphisms. Fertil Steril 102: 1071-1077.e3, 2014. doi: 10.1016/j.fertnstert.2014.06.042.
220. Sykiotis GP, Plummer L, Hughes VA, Au M, Durrani S, Nayak-Young S, Dwyer AA, Quinton R, Hall JE, Gusella JF, Seminara SB, Crowley WF Jr, Pitteloud N. Oligogenic basis of isolated gonadotropin-releasing hormone deficiency. Proc Natl Acad Sci USA 107: 15140-15144, 2010. doi: 10.1073/pnas.1009622107.
221. Szatkowski C, Vallet J, Dormishian M, Messaddeq N, Valet P, Boulberdaa M, Metzger D, Chambon P, Nebigil CG. Prokineticin receptor 1 as a novel suppressor of preadipocyte proliferation and differentiation to control obesity. PLoS One 8: e81175, 2013. doi: 10.1371/journal.pone.0081175.
222. Szekanecz Z, Besenyei T, Paragh G, Koch AE. Angiogenesis in rheumatoid arthritis. Autoimmunity 42: 563-573, 2009. doi: 10.1080/08916930903143083.
223. Szeto TH, Wang XH, Smith R, Connor M, Christie MJ, Nicholson GM, King GF. Isolation of a funnel-web spider polypeptide with homology to mamba intestinal toxin 1 and the embryonic head inducer Dickkopf-1. Toxicon 38: 429-442, 2000. doi: 10.1016/S0041-0101(99)00174-9.
224. Tabata S, Goi T, Nakazawa T, Kimura Y, Katayama K, Yamaguchi A. Endocrine gland-derived vascular endothelial growth factor strengthens cell invasion ability via prokineticin receptor 2 in colon cancer cell lines. Oncol Rep 29: 459-463, 2013. doi: 10.3892/or.2012.2124.
225. Tan PH, Yang LC, Shih HC, Lan KC, Cheng JT. Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat. Gene Ther 12: 59-66, 2005. doi: 10.1038/sj.gt.3302376.
226. Tiberi F, Tropea A, Romani F, Apa R, Marana R, Lanzone A. Prokineticin 1, homeobox A10, and progesterone receptor messenger ribonucleic acid expression in primary cultures of endometrial stromal cells isolated from endometrium of healthy women and from eutopic endometrium of women with endometriosis. Fertil Steril 94: 2558-2563, 2010. doi: 10.1016/j.fertnstert.2010.03.006.
227. Tommiska J, Toppari J, Vaaralahti K, Känsäkoski J, Laitinen EM, Noisa P, Kinnala A, Niinikoski H, Raivio T. PROKR2 mutations in autosomal recessive Kallmann syndrome. Fertil Steril 99: 815-818, 2013. doi: 10.1016/j.fertnstert.2012.11.003.
228. Tsuda M, Kohro Y, Yano T, Tsujikawa T, Kitano J, Tozaki-Saitoh H, Koyanagi S, Ohdo S, Ji RR, Salter MW, Inoue K. JAK-STAT3 pathway regulates spinal astrocyte proliferation and neuropathic pain maintenance in rats. Brain 134: 1127-1139, 2011. doi: 10.1093/brain/awr025.
229. Urayama K, Dedeoglu DB, Guilini C, Frantz S, Ertl G, Messaddeq N, Nebigil CG. Transgenic myocardial overexpression of prokineticin receptor-2 (GPR73b) induces hypertrophy and capillary vessel leakage. Cardiovasc Res 81: 28-37, 2009. doi: 10.1093/cvr/cvn251.
230. Urayama K, Guilini C, Messaddeq N, Hu K, Steenman M, Kurose H, Ert G, Nebigil CG. The prokineticin receptor-1 (GPR73) promotes cardiomyocyte survival and angiogenesis. FASEB J 21: 2980-2993, 2007. doi: 10.1096/fj.07-8116com.
231. Urayama K, Guilini C, Turkeri G, Takir S, Kurose H, Messaddeq N, Dierich A, Nebigil CG. Prokineticin receptor-1 induces neovascularization and epicardial-derived progenitor cell differentiation. Arterioscler Thromb Vasc Biol 28: 841-849, 2008. doi: 10.1161/ATVBAHA.108.162404.
232. Vellani V, Colucci M, Lattanzi R, Giannini E, Negri L, Melchiorri P, McNaughton PA. Sensitization of transient receptor potential vanilloid 1 by the prokineticin receptor agonist Bv8. J Neurosci 26: 5109-5116, 2006. doi: 10.1523/JNEUROSCI.3870-05.2006.
233. Von Hunolstein JJ, Nebigil CG. Can prokineticin prevent obesity and insulin resistance? Curr Opin Endocrinol Diabetes Obes 22: 367-373, 2015. doi: 10.1097/MED.0000000000000185.
234. Wade PR, Palmer JM, Mabus J, Saunders PR, Prouty S, Chevalier K, Gareau MG, McKenney S, Hornby PJ. Prokineticin-1 evokes secretory and contractile activity in rat small intestine. Neurogastroenterol Motil 22: e152-e161, 2010.
235. Wang CY, Tsai HL, Syu JS, Chen TY, Su MT. Primary Cilium-Regulated EG-VEGF Signaling Facilitates Trophoblast Invasion. J Cell Physiol 232: 1467-1477, 2017. doi: 10.1002/jcp.25649.
236. Wang Y, Guo X, Ma H, Lu L, Zhang R. Prokineticin-2 is associated with metabolic syndrome in a middle-aged and elderly Chinese population. Lipids Health Dis 15: 1, 2016. doi: 10.1186/s12944-015-0172-5.
237. Webb EA, Dattani MT. Septo-optic dysplasia. Eur J Hum Genet 18: 393-397, 2010. doi: 10.1038/ejhg.2009.125.
238. Wechselberger C, Puglisi R, Engel E, Lepperdinger G, Boitani C, Kreil G. The mammalian homologues of frog Bv8 are mainly expressed in spermatocytes. FEBS Lett 462: 177-181, 1999. doi: 10.1016/S0014-5793(99)01473-8.
239. Wen S, Wilson DT, Kuruppu S, Korsinczky ML, Hedrick J, Pang L, Szeto T, Hodgson WC, Alewood PF, Nicholson GM. Discovery of an MIT-like atracotoxin family: spider venom peptides that share sequence homology but not pharmacological properties with AVIT family proteins. Peptides 26: 2412-2426, 2005. doi: 10.1016/j.peptides.2005.05.012.
240. Xin H, Lu R, Lee H, Zhang W, Zhang C, Deng J, Liu Y, Shen S, Wagner KU, Forman S, Jove R, Yu H. G-protein-coupled receptor agonist BV8/prokineticin-2 and STAT3 protein form a feed-forward loop in both normal and malignant myeloid cells. J Biol Chem 288: 13842-13849, 2013. doi: 10.1074/jbc.M113.450049.
241. Xiong YC, Li XM, Wang XJ, Liu YQ, Qiu F, Wu D, Gan YB, Wang BH, Hu WP. Prokineticin 2 suppresses GABA-activated current in rat primary sensory neurons. Neuropharmacology 59: 589-594, 2010. doi: 10.1016/j.neuropharm.2010.08.014.
242. Yan B, Wei JJ, Yuan Y, Sun R, Li D, Luo J, Liao SJ, Zhou YH, Shu Y, Wang Q, Zhang GM, Feng ZH. IL-6 cooperates with G-CSF to induce protumor function of neutrophils in bone marrow by enhancing STAT3 activation. J Immunol 190: 5882-5893, 2013. doi: 10.4049/jimmunol.1201881.
243. Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP, Lin PC. Expansion of myeloid immune suppressor Gr_CD11b_cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 6: 409-421, 2004. doi: 10.1016/j.ccr.2004.08.031.
244. Yin W, Liu H, Peng Z, Chen D, Li J, Li JD. Mechanisms that underlie the internalization and extracellular signal regulated kinase 1/2 activation by PKR2 receptor. Cell Signal 26: 1118-1124, 2014. doi: 10.1016/j.cellsig.2014.01.031.
245. Yuill EA, Hoyda TD, Ferri CC, Zhou QY, Ferguson AV. Prokineticin 2 depolarizes paraventricular nucleus magnocellular and parvocellular neurons. Eur J Neurosci 25: 425-434, 2007. doi: 10.1111/j.1460-9568.2006.05293.x.
246. Zeleznik AJ. Follicle selection in primates: “many are called but few are chosen”. Biol Reprod 65: 655-659, 2001. doi: 10.1095/biolreprod65.3.655.
247. Zhang C, Ng KL, Li JD, He F, Anderson DJ, Sun YE, Zhou QY. Prokineticin 2 is a target gene of proneural basic helix-loop-helix factors for olfactory bulb neurogenesis. J Biol Chem 282: 6917-6921, 2007. doi: 10.1074/jbc.C600290200.
248. Zhang C, Truong KK, Zhou QY. Efferent projections of prokineticin 2 expressing neurons in the mouse suprachiasmatic nucleus. PLoS One 4: e7151, 2009. doi: 10.1371/journal.pone.0007151.
249. Zhang L, Yang N, Conejo-Garcia JR, Katsaros D, Mohamed-Hadley A, Fracchioli S, Schlienger K, Toll A, Levine B, Rubin SC, Coukos G. Expression of endocrine glandderived vascular endothelial growth factor in ovarian carcinoma. Clin Cancer Res 9: 264-272, 2003.
250. Zhong C, Qu X, Tan M, Meng YG, Ferrara N. Characterization and regulation of bv8 in human blood cells. Clin Cancer Res 15: 2675-2684, 2009. doi: 10.1158/1078-0432.CCR-08-1954.
251. Zhou QY. The prokineticins: a novel pair of regulatory peptides. Mol Interv 6: 330-338, 2006. doi: 10.1124/mi.6.6.6.
252. Zhou QY, Cheng MY. Prokineticin 2 and circadian clock output. FEBS J 272: 5703-5709, 2005. doi: 10.1111/j.1742-4658.2005.04984.x.
253. Zhou W, Li JD, Hu WP, Cheng MY, Zhou QY. Prokineticin 2 is involved in the thermoregulation and energy expenditure. Regul Pept 179: 84-90, 2012. doi: 10.1016/j.regpep.2012.08.003.
254. Zhou XT, Chen DN, Xie ZQ, Peng Z, Xia KD, Liu HD, Liu W, Su B, Li JD. Functional analysis of the distal region of the third intracellular loop of PROKR2. Biochem Biophys Res Commun 439: 12-17, 2013. doi: 10.1016/j.bbrc.2013.08.039.